# OnCo record paper-mariposa-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-mariposa-nejm-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-mariposa-nejm-2024" ;
  schema:name "MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer"@en ;
  schema:description "Combining an EGFR-MET bispecific antibody with a third-generation EGFR pill beat osimertinib alone, delaying progression by about seven months and later improving survival, at the cost of more side effects."@en ;
  schema:url <https://onco.cc/key-papers/paper-mariposa-nejm-2024/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2403614>, <https://clinicaltrials.gov/study/NCT04487080>, <https://pubmed.ncbi.nlm.nih.gov/38924756/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2403614> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Cho BC, Lu S, Felip E, et al." ;
  onco:related <https://onco.cc/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/>, <https://onco.cc/key-papers/paper-flaura-nejm-2018/>, <https://onco.cc/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/lazertinib/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:institutions <https://onco.cc/institutions/severance/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/first-line/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/driver-mutation/> ;
  onco:trials <https://onco.cc/trials/mariposa/>, <https://onco.cc/trials/flaura2/> ;
  onco:people <https://onco.cc/people/cho-byoung-chul/>, <https://onco.cc/people/lu-shun/>, <https://onco.cc/people/enriqueta-felip/>, <https://onco.cc/people/lee-se-hoon/>, <https://onco.cc/people/benjamin-besse/>, <https://onco.cc/people/prabhash-kumar/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-combination-space/> ;
  onco:journals <https://onco.cc/journals/nejm/> .